School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Med Virol. 2023 Feb;95(2):e28435. doi: 10.1002/jmv.28435.
The SPF10-PCR-based line probe assay (LiPA-25) for human papillomavirus (HPV) genotyping with high analytical sensitivity and specificity was widely used in HPV vaccine clinical trials and epidemiologic studies. In the study, we aimed to compare a novel GP5+/6+-PCR-based reverse dot blot hybridization assay (Yaneng-23) with LiPA-25. The performance of two assays was evaluated in 1735 cervical swab and 117 tissue samples, with a focus on 19 common HPV types (14 high-risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68/73; 5 low-risk: 6, 11, 42, 43, and 53). A total of 1197 (69.0%) swab samples were identified as HPV-positive by two assays. Of these, 878 (73.4%) samples displayed absolute agreement (concordant), 255 (21.3%) showed additional or fewer types (compatible), and the remaining 64 (5.3%) samples were discordant. Additionally, the two assays showed an excellent strength of agreement for 19 HPV-combined detection (κ = 0.886) and 17 individual HPV types (all κ > 0.800), and displayed a good agreement for HPV39 (κ = 0.780) and 42 (κ = 0.699). Yaneng-23 was more sensitive than LiPA-25 for HPV58, 59, 68/73, 42, 43 and 53 (McNemar's test: all p < 0.05), while LiPA-25 was more sensitive for HPV31, 39, 52, and 66 than Yaneng-23 (all p < 0.05). In 113 HPV-positive tissue specimens, the identification of genotypes was 82.3% identical and 17.7% compatible. The agreement between the tests for HPV45 (κ = 0.796) and 51 (κ = 0.742) was good, and for other types (all κ > 0.843) and 19 HPV-combined detection (κ = 0.929) was perfect (all p > 0.05). In conclusion, Yaneng-23 and LiPA-25 are comparable. Yaneng-23 could be used for the detection and genotyping of HPV in cervical samples for epidemiological and vaccine studies worldwide.
基于 SPF10-PCR 的线性探针分析(LiPA-25)用于人乳头瘤病毒(HPV)基因分型,具有高分析灵敏度和特异性,已广泛应用于 HPV 疫苗临床试验和流行病学研究。在本研究中,我们旨在比较一种新的基于 GP5+/6+-PCR 的反向斑点印迹杂交检测(Yaneng-23)与 LiPA-25。我们评估了两种检测方法在 1735 例宫颈拭子和 117 例组织样本中的性能,重点关注 19 种常见 HPV 类型(14 种高危型:16、18、31、33、35、39、45、51、52、56、58、59、66 和 68/73;5 种低危型:6、11、42、43 和 53)。两种检测方法共检测出 1197 例(69.0%)宫颈拭子 HPV 阳性。其中,878 例(73.4%)样本显示绝对一致(相符),255 例(21.3%)显示额外或更少的类型(兼容),64 例(5.3%)样本显示不一致。此外,两种检测方法对 19 种 HPV 联合检测(κ=0.886)和 17 种 HPV 单独检测(均κ>0.800)的一致性强度均较好,HPV39(κ=0.780)和 42(κ=0.699)的一致性也较好。Yaneng-23 对 HPV58、59、68/73、42、43 和 53 的检测敏感性均高于 LiPA-25(McNemar 检验:均 p<0.05),而 LiPA-25 对 HPV31、39、52 和 66 的检测敏感性均高于 Yaneng-23(均 p<0.05)。在 113 例 HPV 阳性组织标本中,基因型鉴定的一致性为 82.3%,兼容性为 17.7%。两种检测方法对 HPV45(κ=0.796)和 51(κ=0.742)的一致性较好,对其他类型(均κ>0.843)和 19 种 HPV 联合检测(κ=0.929)的一致性为极好(均 p>0.05)。总之,Yaneng-23 和 LiPA-25 具有可比性。Yaneng-23 可用于全球 HPV 流行病学和疫苗研究中宫颈样本的 HPV 检测和基因分型。